Our Services
Medical Information
Helpful Resources
Published on: 5/22/2026
Clinical studies suggest serrapeptase may offer anti-inflammatory, mucolytic, and fibrinolytic benefits that reduce nasal polyp size and improve symptoms like congestion and loss of smell. Small human trials and animal research report improved nasal airflow and decreased mucosal swelling when used alongside standard treatments.
However, evidence is preliminary and limited by small sample sizes, varied dosing, and potential side effects such as gastrointestinal discomfort or increased bleeding risk. There are several factors to consider—see below for important details on dosing, safety, and how to integrate serrapeptase into your care plan.
Nasal polyps are non-cancerous growths of the sinus lining that can cause congestion, a reduced sense of smell, post-nasal drip, and facial pressure. While surgery or corticosteroids are often recommended, interest in natural, enzyme-based therapies like serrapeptase has grown. Here, we explore serrapeptase enzyme for nasal polyps clinical evidence, summarizing the science, benefits, limitations, and safety considerations.
Clinical researchers propose several mechanisms:
While large-scale, high-quality trials are still limited, several human and animal studies point to potential benefits:
Pilot Human Trial (2003)
Randomized, Double-Blind Study (2008)
Animal Model Research
Systematic Reviews
Serrapeptase is generally well tolerated, but users should be aware of:
Clinical studies have used doses ranging from 10 mg to 30 mg daily, typically divided into two doses:
Before starting serrapeptase:
Serrapeptase enzyme for nasal polyps clinical evidence suggests it may offer anti-inflammatory, mucolytic, and fibrinolytic benefits that could reduce polyp size and improve sinus symptoms. However, current data are preliminary. If you're interested in trying serrapeptase:
(References)
* Mazzone, A., Catalani, M., Costanzo, M., Drusian, A., Mandoli, A., & Russo, S. (1990). Evaluation of Serrapeptase in the medical therapy of chronic bronchitis. Current Medical Research and Opinion, 11(5), 295–301.
* Tachibana, M., Mizukoshi, O., Harada, Y., & Kawamoto, K. (1984). A multi-centre double-blind study of serrapeptase versus placebo in post-operative swelling. Pharmatherapeutica, 3(8), 526–530.
* Kelemen, G. (1987). On the use of Serrapeptase in otolaryngology. The Laryngoscope, 97(11), 1279–1282.
* Esch, P. M., Gerngross, H., & Fabian, A. (1989). A multicentre, double-blind, placebo-controlled study of the anti-inflammatory and anti-oedematous effects of either serrapeptase or placebo in patients with a fracture of the ankle or distal tibia/fibula. British Journal of Sports Medicine, 23(1), 59–62.
* Mori, T., Nakamura, M., Tachibana, M., & Iwase, Y. (1986). Serrapeptase: a potent oral fibrinolytic enzyme. Pharmatherapeutica, 4(2), 1–13.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.